MARKET

SRRA

SRRA

SIERRA ONCOLOGY
NASDAQ

Real-time Quotes | Nasdaq Last Sale

14.01
+0.23
+1.67%
Closed 16:00 12/04 EST
OPEN
14.11
PREV CLOSE
13.78
HIGH
14.27
LOW
13.89
VOLUME
5.78K
TURNOVER
--
52 WEEK HIGH
22.00
52 WEEK LOW
8.55
MARKET CAP
154.68M
P/E (TTM)
-1.0043
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Sierra Oncology to Host KOL Panel Event to Discuss Updated Phase 3 Myelofibrosis Data Presented at ASH
Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, today announced it will host an analyst and investor event on Wednesday, December 16, 2020 at 10:00 am ET. The event will feature three leading myelofibrosis experts:
PR Newswire · 4d ago
Sierra Oncology Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
VANCOUVER, BC, /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company focused on the Phase 3 execution, registration and potential commercialization of momelotinib, a novel drug that may address serious unmet needs in myelofibrosis, granted a stock option to a new employee as approved by the Compensation Committee of the Company's Board of Directors, under Sierra Oncology's 2018 Equity Inducement Plan.
PR Newswire - PRF · 11/25 12:00
Who Has Been Buying Sierra Oncology, Inc. (NASDAQ:SRRA) Shares?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...
Simply Wall St. · 11/18 07:33
Sierra Oncology to Present at 2020 Jefferies Virtual London Healthcare Conference
, /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company focused on the Phase 3 execution, registration and potential commercialization of momelotinib, a novel drug that may address serious unmet needs in myelofibrosis, today announced that President and Chief Executive Officer , MBBS, PhD, will present an overview of the company at the Jefferies Virtual London Healthcare Conference taking place .
PR Newswire - PRF · 11/12 12:00
Sierra Oncology to Present at 2020 Jefferies Virtual London Healthcare Conference
Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company focused on the Phase 3 execution, registration and potential commercialization of momelotinib, a novel drug that may address serious unmet needs in myelofibrosis, today announced that President and Chief Executive Officer Stephen Dilly, MBBS, PhD, will present an overview of the company at the Jefferies Virtual London Healthcare Conference taking place November 17-19, 2020.
PR Newswire · 11/12 12:00
Sierra Oncology to Report Momelotinib Long-term Overall Survival Data in Oral Presentation at ASH 2020
- Efficacy data for momelotinib in myelofibrosis patients by baseline platelet levels also to be presented -
PR Newswire · 11/05 13:00
Sierra Oncology to Report Momelotinib Long-term Overall Survival Data in Oral Presentation at ASH 2020
Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company focused on the Phase 3 execution, registration and potential commercialization of momelotinib, a novel drug that may address serious unmet needs in myelofibrosis, today announced two abstracts have been selected for presentation at the 62nd American Society of Hematology (ASH) Annual Meeting being held December 5-8, 2020.
PR Newswire · 11/05 13:00
Sierra Oncology Reports Third Quarter 2020 Results
Sierra Oncology Reports Third Quarter 2020 Results
CNW Group · 11/05 12:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SRRA. Analyze the recent business situations of SIERRA ONCOLOGY through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SRRA stock price target is 25.00 with a high estimate of 32.00 and a low estimate of 20.00.
EPS
Institutional Holdings
Institutions: 66
Institutional Holdings: 20.30M
% Owned: 183.89%
Shares Outstanding: 11.04M
TypeInstitutionsShares
Increased
6
340.68K
New
5
-205.80K
Decreased
4
30.57K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.89%
Pharmaceuticals & Medical Research
+1.72%
Key Executives
Chairman/Independent Director
Robert Pelzer
President/Chief Executive Officer/Director
Stephen Dilly
Chief Financial Officer
Sukhi Jagpal
General Counsel
Christina Thomson
Other
Barbara Klencke
Other
Mark Kowalski
Other
Kevin Norrett
Other
William Turner
Director
Craig Collard
Independent Director
Gaurav Aggarwal
Independent Director
Andrew Allen
Independent Director
Mona Ashiya
Independent Director
Jeffrey Cooper
Independent Director
Josh Richardson
Independent Director
Andrew Sinclair
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About SRRA
Sierra Oncology, Inc. is late stage drug development company. The Company is focused on advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology. Momelotinib, the Company’s lead drug candidate, is a potent, selective and orally-bioavailable janus kinase one (JAK1), janus kinase two (JAK2) and activin a receptor type one (ACVR1) inhibitor with a differentiated therapeutic profile in myelofibrosis. The Company is also developing a portfolio of deoxyribonucleic acid (DNA) damage response (DDR) assets, consisting of SRA737 and SRA141. SRA737 is a potent, selective, orally bioavailable small molecule inhibitor of checkpoint kinase 1 (Chk1), a key regulator of cell cycle progression and the DDR network. SRA141 is a potent, selective, orally bioavailable small molecule inhibitor of Cell division cycle 7 kinase (Cdc7).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Sierra Oncology Inc stock information, including NASDAQ:SRRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SRRA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SRRA stock methods without spending real money on the virtual paper trading platform.